Allard Kaptein, PhD, is a serial entrepreneur/scientist and currently is Managing Director of Genase Therapeutics. Before Genase Therapeutics he was EVP Discovery at Acerta Pharma, a company for which he was one of the founders. In the founding phase he played a crucial role in fund raising and in obtaining an exclusive license from MSD, for a chemical series that included the now FDA and EMA approved drug acalabrutinib. In 2015 he was part of the team involved in discussions with big pharma companies interested in Acerta Pharma and/or the covalent BTK inhibitor program. Discussions that resulted in Acerta Pharma becoming a majority owned subsidiary of AstraZeneca.

Allard joined the pharmaceutical industry in 1994 and worked in different project and line management positions at Glaxo, GlaxoWellcome, Organon, Schering Plough and MSD, on cardiovascular disease, autoimmune disease and oncology.